Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
+44 7868 792050
ISSN: 2329-8790
+44 7868 792050
Hitoshi Hanamoto
Japan
Research Article
Once-weekly Bortezomib in Combination with Reduced-dose Dexamethasone and Continuous Low-dose Oral Cyclophosphamide for Elderly Patients with Multiple Myeloma
Author(s): Hideo Yagi, Aki Fujii, Syuji Minamoto, Mariko Fujita, Keiko Yamazaki, Hitoshi Hanamoto and Kazuo TsubakiHideo Yagi, Aki Fujii, Syuji Minamoto, Mariko Fujita, Keiko Yamazaki, Hitoshi Hanamoto and Kazuo Tsubaki
CyBorD is one of the most effective triplet regimens for both transplant-eligible and ineligible patients with multiple myeloma. In comparison, once-weekly bortezomib induction therapy with a reduced dosage of dexamethasone (modified-CyBorD) showed less toxicity but an equally high response rate. However, this modification still resulted in bortezomib-induced PN in more than half of patients. We therefore introduced a once-weekly schedule of bortezomib combined with continuous low-dose oral cyclophosphamide and reduced dosage of dexamethasone (reduced-CyBorD) in transplantineligible patients with multiple myeloma in our hospital. A total of 32 patients, including 20 who were newly diagnosed and 12 who were refractory/resistant, were treated with reduced-CyBorD, and the regimen’s efficacy and safety were evaluated. The median age was 72 years; 17 patients were male and 15 were fe.. View More»
DOI:
10.4172/2329-8790.1000261